Dr Reddys Laboratories Ltd Corporate Actions

Dr. Reddy’s Laboratories Sells 14 ANDAs to Senores Pharma

 Copy Link

Senores Pharmaceuticals intends to fund the acquisition through proceeds from its IPO, which raised ₹5.82 billion in December.

Top Stocks for - 27th February 2025

 Copy Link

Here are some of the stocks that may see significant price movement today: KPI Green, Tata Power, UltraTech Cement, etc.

Dr Reddy’s Hyderabad API Unit Gets USFDA VAI Classification

 Copy Link

Dr Reddy's Laboratories third quarter net profit rose 2.5% year-on-year (YoY) to ₹1,413.3 crore. 

Dr Reddy’s Laboratories Q3 net profit zooms ~3%

 Copy Link

The company logged a growth of 15.9% in its revenue from operations at ₹8,358.60 Crore versus ₹7,215 Crore in Q3FY24.

Top Stocks for Today - 24th January 2025

 Copy Link

Here are some of the stocks that may see significant price movement today: Indus Towers, Dr Reddy’s Laboratories, Mankind Pharma, etc.

Top Stocks for today - 6th December 2024

 Copy Link

Here are some of the stocks that may see significant price movement today: Dr Reddy’s Laboratories, RITES, Canara Bank, etc.

Dr Reddy’s launches first immuno-onco drug in India

 Copy Link

Dr Reddy's already signed a license and commercialisation deal for Toripalimab with Shanghai Junshi Biosciences Co. Ltd in 2023.

Dr Reddy’s Bollaram Facility Receives USFDA Form 483 with 7 Observations

 Copy Link

Dr Reddy’s Laboratories shares has gained a total of 5.62% in the last one year, and 2.45% since the beginning of the year.

Top Stocks for today - 21st November 2024

 Copy Link

Here are some of the stocks that may see significant price movement today: UPL, Tata Power, JSW Steel, Dr Reddy’s, etc.

Dr Reddy’s posts 15% y-o-y decline in Q2 net profit at ₹1,255 Crore

 Copy Link

EBITDA for the quarter increased 5% year-on-year to ₹2,280 Crore between July and September 2024, while margins improved modestly to 28.4%.